115 research outputs found
Complementary and alterative treatments in functional dyspepsia
INTRODUCTION AND AIM: The popularity of complementary and alternative medicine (CAM) in treating functional gastrointestinal disorders (FGIDs) has steadily increased in Western countries. We aimed at analyzing available data on CAM effectiveness in functional dyspepsia (FD) patients.
METHODS: A bibliographical search was performed in PubMed using the following keywords: "complementary/alternative medicineâ, âhypnosisâ, âacupunctureâ and/or âfunctional dyspepsiaâ.
RESULTS: In community settings, almost 50% of patients with FGIDs used CAM therapies. Herbal remedies consist in multi-component preparations, whose mechanisms of action have not been systematically clarified. Few studies analyzed the effectiveness of Acupuncture in Western countries, yielding conflicting results and possibly reflecting a population bias of this treatment. Hypnosis has been extensively used in irritable bowel syndrome, but few data support its role in treating FD.
CONCLUSIONS: Although some supporting well-designed studies have been recently performed, additional randomized control trials are needed before stating any recommendation on CAM effectiveness in treating FD
Complementary and alternative treatment in functional dyspepsia
The popularity of complementary and alternative medicine (CAM) in treating functional gastrointestinal disorders (FGIDs) has steadily increased in Western countries. We aimed at analyzing available data on CAM effectiveness in functional dyspepsia (FD) patients
Endocannabinoid-related compounds in gastrointestinal diseases
The endocannabinoid system (ECS) is an endogenous signalling pathway involved in the control of several gastrointestinal (GI) functions at
both peripheral and central levels. In recent years, it has become apparent that the ECS is pivotal in the regulation of GI motility, secretion and
sensitivity, but endocannabinoids (ECs) are also involved in the regulation of intestinal inflammation and mucosal barrier permeability, suggesting
their role in the pathophysiology of both functional and organic GI disorders. Genetic studies in patients with irritable bowel syndrome (IBS)
or inflammatory bowel disease have indeed shown significant associations with polymorphisms or mutation in genes encoding for cannabinoid
receptor or enzyme responsible for their catabolism, respectively. Furthermore, ongoing clinical trials are testing EC agonists/antagonists in the
achievement of symptomatic relief from a number of GI symptoms. Despite this evidence, there is a lack of supportive RCTs and relevant data
in human beings, and hence, the possible therapeutic application of these compounds is raising ethical, political and economic concerns. More
recently, the identification of several EC-like compounds able to modulate ECS function without the typical central side effects of cannabinomimetics
has paved the way for emerging peripherally acting drugs. This review summarizes the possible mechanisms linking the ECS to GI
disorders and describes the most recent advances in the manipulation of the ECS in the treatment of GI diseases
S100B Protein Stimulates Proliferation and Angiogenic Mediators Release through RAGE/pAkt/mTOR Pathway in Human Colon Adenocarcinoma Caco-2 Cells
Chronic inflammation and angiogenesis are associated with colonic carcinogenesis. Enteric glia-derived S100B protein has been proposed as an "ideal bridge", linking colonic inflammation and cancer, given its dual ability to up-regulate nuclear factor-kappaB (NF-ÎșB) transcription via receptor for advanced glycation end products (RAGE) signaling and to sequestrate wild type pro-apoptotic wild type (wt)p53. However, its pro-angiogenic effects on cancer cells are still uninvestigated. To this aim, we evaluated the effect of exogenous S100B (0.05-5 ”M) protein alone or in the presence of S100B blocking monoclonal antibody (mAb) (1:105-1:104v/v diluted) on (1) cultured Caco-2 cells proliferation, migration and invasiveness in vitro, respectively by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)-formazan, wound healing and matrigel invasion assays and (2) its effect on the release of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF) by ELISA and immunofluorescence analyses. The effect of S100B alone or in the presence of S100BmAb was then investigated on RAGE/pAkt/mammalian target of rapamycin (mTOR) signaling pathway by immunoblot analysis. Our results showed that S100B markedly increases proliferation and invasiveness of Caco-2 cells, through the release of pro-angiogenic VEGF and NO paralleled to a significant decrease of wtp53 expression mediated by RAGE-p38 mitogen-activated protein kinase (MAPK)/pAkt-mTOR and hypoxia-inducible factor 1-alpha (HIF1α) pathways. Such effects were counteracted by S100BmAb, indicating that S100B targeting is a potential approach to inhibit colon carcinoma proliferation and angiogenesis
The potential of cannabidiol in the COVIDâ19 pandemic.
Identifying candidate drugs effective in the new coronavirus disease 2019 (Covid-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that Cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and progression of the disease for several reasons: 1) High-CBD Cannabis Sativa extracts are able to downregulate the expression of the two key receptors for SARS-CoV2 in several models of human epithelia 2) CBD exerts a wide range of immunomodulatory and anti-inflammatory effects and it can mitigate the uncontrolled cytokine production featuring Acute Lung Injury 3) Being a PPARÎł agonist, it can display a direct antiviral activity 4) PPARÎł agonists are regulators of fibroblast/myofibroblast activation and can inhibit the development of pulmonary fibrosis, thus ameliorating lung function in recovered patients. We hope our hypothesis, corroborated by several preclinical evidence, will inspire further targeted studies to test CBD as a support drug against the COVID-19 pandemic
Enteric glia: A new player in inflammatory bowel diseases
In addition to the well-known involvement of macrophages and neutrophils, other cell types have been recently reported to substantially contribute to the onset and progression of inflammatory bowel diseases (IBD). Enteric glial cells (EGC) are the equivalent cell type of astrocyte in the central nervous system (CNS) and share with them many neurotrophic and neuro-immunomodulatory properties. This short review highlights the role of EGC in IBD, describing the role played by these cells in the maintenance of gut homeostasis, and their modulation of enteric neuronal activities. In pathological conditions, EGC have been reported to trigger and support bowel inflammation through the specific over-secretion of S100B protein, a pivotal neurotrophic factor able to induce chronic inflammatory changes in gut mucosa. New pharmacological tools that may improve the current therapeutic strategies for inflammatory bowel diseases (IBD), lowering side effects (i.e. corticosteroids) and costs (i.e. anti-TNFα monoclonal antibodies) represent a very important challenge for gastroenterologists and pharmacologists. Novel drugs capable to modulate enteric glia reactivity, limiting the pro-inflammatory release of S100B, may thus represent a significant innovation in the field of pharmacological interventions for inflammatory bowel diseases
High-fat diet impairs duodenal barrier function and elicits glia-dependent changes along the gut-brain axis that are required for anxiogenic and depressive-like behaviors
Background: Mood and metabolic disorders are interrelated and may share common pathological processes. Autonomic neurons link the brain with the gastrointestinal tract and constitute a likely pathway for peripheral metabolic challenges to affect behaviors controlled by the brain. The activities of neurons along these pathways are regulated by glia, which exhibit phenotypic shifts in response to changes in their microenvironment. How glial changes might contribute to the behavioral effects of consuming a high-fat diet (HFD) is uncertain. Here, we tested the hypothesis that anxiogenic and depressive-like behaviors driven by consuming a HFD involve compromised duodenal barrier integrity and subsequent phenotypic changes to glia and neurons along the gut-brain axis.
Methods: C57Bl/6 male mice were exposed to a standard diet or HFD for 20 weeks. Bodyweight was monitored weekly and correlated with mucosa histological damage and duodenal expression of tight junction proteins ZO-1 and occludin at 0, 6, and 20 weeks. The expression of GFAP, TLR-4, BDNF, and DCX were investigated in duodenal myenteric plexus, nodose ganglia, and dentate gyrus of the hippocampus at the same time points. Dendritic spine number was measured in cultured neurons isolated from duodenal myenteric plexuses and hippocampi at weeks 0, 6, and 20. Depressive and anxiety behaviors were also assessed by tail suspension, forced swimming, and open field tests.
Results: HFD mice exhibited duodenal mucosa damage with marked infiltration of immune cells and decreased expression of ZO-1 and occludin that coincided with increasing body weight. Glial expression of GFAP and TLR4 increased in parallel in the duodenal myenteric plexuses, nodose ganglia, and hippocampus in a time-dependent manner. Glial changes were associated with a progressive decrease in BDNF, and DCX expression, fewer neuronal dendritic spines, and anxiogenic/depressive symptoms in HFD-treated mice. Fluorocitrate (FC), a glial metabolic poison, abolished these effects both in the enteric and central nervous systems and prevented behavioral alterations at week 20.
Conclusions: HFD impairs duodenal barrier integrity and produces behavioral changes consistent with depressive and anxiety phenotypes. HFD-driven changes in both peripheral and central nervous systems are glial-dependent, suggesting a potential glial role in the alteration of the gut-brain signaling that occurs during metabolic disorders and psychiatric co-morbidity
Percutaneous endoscopic jejunostomy (PEJ) in patients with dumping syndrome: Evaluation of our center on a series of clinical cases
Background: The Dumping syndrome occurs in a variable percentage
of subjects undergoing surgery involving the esophageal
and gastric district. The treatment makes use of the introduction of
dietary measures and arti!cial nutrition, especially the internal
one. This study evaluates the experience of a single center
regarding the use of percutaneous endoscopic jejunostomy (PEJ) in
patients developing the dumping syndrome.
Methods: We evaluated the case history of our department, of all
patients operated on at the level of the upper gastrointestinal tract,
who had manifested symptoms referable to the Dumping syndrome
in the postoperative period.We have identi!ed 3, which we
have carried out further investigations to con!rm the presence of
an accelerated gastric emptying, and given the poor results obtained
with dietary modi!cations and drug therapy, we have
implemented a feeding through enteral nutrition, through a jejunal
probe. PEG/J positioned by Pull technique, and subsequently
replaced after 8 months.
Results: Clinically, patients did not develop short- or long-term
complications, symptoms were signi!cantly reduced, and they
gained weight. Psychologically, the anxiety disorders related to
nutrition have improved.
Conclusions: By means of percutaneous endoscopic jejunostomy,
the symptoms related to hypoglycemic crises following the
hyperinsulinemic response to the ingestion of carbohydrates in
patients with Dumping were attenuated and the anxiety of eating
was lessened. Although limited to a few cases, we believe this form
of nutrition is the best for patients with dumping
Rifaximin improves Clostridium difficile toxin A-induced toxicity in Caco-2 cells by the PXR-dependent TLR4/MyD88 /NF-?B pathway
Background: Clostridium difficile infections (CDIs) caused by Clostridium difficile toxin A (TcdA) lead to severe ulceration,
inflammation and bleeding of the colon, and are difficult to treat.
Aim: The study aimed to evaluate the effect of rifaximin on TcdA-induced apoptosis in intestinal epithelial cells and investigate the role of PXR in its mechanism of action.
Methods: Cacoâ2 cells were incubated with TcdA and treated with rifaximin (0.1â10 ÎŒM) with or without ketoconazole (10 ÎŒM). The transepithelial electrical resistance (TEER) and viability of the treated cells was determined. Also, the expression of zona occludensâ1 (ZOâ1), tollâlike receptor 4 (TLR4), Bclâ2âassociated X protein (Bax), transforming growth factorâÎČâactivated kinaseâ1 (TAK1), myeloid differentiation factor 88 (MyD88) and nuclear factorâkappaB (NFâÎșB) was determined.
Results Rifaximin treatment (0.1, 1.0 and 10 ÎŒM) caused a significant and concentration-dependent increase in the TEER of Caco-2 cells (360%, 480% and 680% vs TcdA treatment) 24 hours after the treatment and improved their viability (61%, 79% and 105%). Treatment also concentration-dependently decreased the expression of Bax protein (â29%, â65% and â77%) and increased the expression of ZO-1 (25%, 54% and 87%) and occludin (71%, 114% and 262%) versus TcdA treatment. The expression of TLR4 (â33%, â50% and â75%), MyD88 (â29%, â60% and â81%) and TAK1 (â37%, â63% and â79%) were also reduced with rifaximin versus TcdA treatment. Ketoconazole treatment inhibited these effects.
Conclusions: Rifaximin improved TcdAâinduced toxicity in Cacoâ2 cells by the PXRâdependent TLR4/MyD88/NFâÎșB pathway mechanism, and may be useful in the treatment of CDIs
Impaired duodenal Palmitoylethanolamide release underlies acid-induced mast cells activation in Functional Dyspepsia
Acid hypersensitivity is claimed to be a symptomatic trigger in functional dyspepsia (FD); however, the neuroimmune pathway(s) and the mediators involved in this process have not been systematically investigated. Palmitoylethanolamide (PEA) is an endogenous compound, able to modulate nociception and inflammation, but its role in FD has never been assessed
- âŠ